Skip to main navigation Skip to search Skip to main content

Concomitant Liver Biopsy During Bariatric Surgery: No Increase in Major Complications or Readmissions but Associated with Higher Transfusion Requirements - An Analysis of the MBSAQIP Database

  • Royal College of Surgeons in Ireland - Bahrain
  • Cleveland Clinic Foundation
  • University of Virginia
  • Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
  • Cleveland Clinic Abu Dhabi

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Introduction: Concomitant liver biopsy during bariatric surgery has gained interest for diagnostic and research purposes, particularly in studying obesity-related liver disease. However, comprehensive data on safety remains limited using recent national databases. Methods: A retrospective analysis of the MBSAQIP database from 2020 to 2022 was conducted. Patients undergoing primary Roux-en-Y gastric bypass or sleeve gastrectomy with or without concomitant liver biopsy were included. Primary outcomes were 30-day major complications (Clavien-Dindo grade III and IV) and mortality. Separate multivariable analyses were performed for bleeding-related complications including postoperative bleeding, transfusion requirements, and reoperation. Multivariable logistic regression analysis determined if concomitant liver biopsy independently predicted adverse outcomes. Results: Of 511,981 patients, 30,819 (6.02%) underwent concomitant liver biopsy. Biopsy patients had higher rates of diabetes (28.25% vs 22.65%, p < 0.001) and hyperlipidemia (25.20% vs 22.14%, p < 0.001). Mean operative time was longer in the biopsy group (96.10 vs 83.59 min, p < 0.001). Unadjusted analysis showed higher rates of major complications (Clavien-Dindo grade III and IV) (3.15% vs 2.70%, p < 0.001) and 30-day readmission (3.32% vs 2.86%, p < 0.001) in the biopsy group. However, on multivariable analysis, concomitant liver biopsy was not independently predictive of major complications (OR 0.91, 95%CI 0.79–1.04, p = 0.164) or 30-day readmission (OR 1.06, 95%CI 0.94–1.21, p = 0.344). Separate multivariable analyses for bleeding-related complications revealed that concomitant liver biopsy was independently associated with increased postoperative bleeding (OR 1.203, 95%CI 1.018–1.422, p = 0.030) and transfusion requirements (OR 1.171, 95%CI 1.028–1.334, p = 0.018), but not with reoperation (OR 1.016, 95%CI 0.908–1.138, p = 0.783). Conclusion: After adjusting for patient factors, concomitant liver biopsy during bariatric surgery does not independently increase the risk of major complications (Clavien-Dindo grade III and IV), readmission, or mortality. However, it is associated with increased bleeding and transfusion complications. These findings support that liver biopsy can be performed during bariatric surgery, though clinicians should be prepared for increased bleeding-related risks and blood product utilization.

Original languageEnglish
Pages (from-to)4752-4765
Number of pages14
JournalObesity Surgery
Volume35
Issue number11
DOIs
StatePublished - Nov 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Bariatric surgery
  • Liver biopsy
  • MBSAQIP
  • Obesity
  • Patient safety
  • Surgical complications

Fingerprint

Dive into the research topics of 'Concomitant Liver Biopsy During Bariatric Surgery: No Increase in Major Complications or Readmissions but Associated with Higher Transfusion Requirements - An Analysis of the MBSAQIP Database'. Together they form a unique fingerprint.

Cite this